Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
- 1 August 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Oncology
- Vol. 3 (8), 448-457
- https://doi.org/10.1038/ncponc0558
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Cancer Invasion and MetastasisOncology, 2005
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005
- Targeted cancer therapyNature, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- A resource for large-scale RNA-interference-based screens in mammalsNature, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002